Drugs / REGN22530
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07675824 | Jul 2026 → Jul 2029 expected | ocular hypertension, open-angle glaucoma | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN22530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07675824 ↗ |
| Action | Inhibit | “REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure.” NCT07675824 ↗ |